Yervoy

Active substance

Ipilimumab

Holder

BMS

Status

Running

Indication

Treatment-Naïve Intermediate and Poor Risk Patients with Advanced or Metastatic Renal Cell Carcinoma in combination with Opdivo® (nivolumab)

Public documents

Approbation

Information for the patient

Informed consent

Last update

26/03/2019

Last updated on 26/03/2019